# China NMPA Drug Inspection - Guangzhou Xiangxue Pharmaceutical Co., Ltd. - Antiviral oral liquid

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/guangzhou-xiangxue-pharmaceutical-co-ltd/7543aed0-3345-499b-bf82-d2417460daa2/
Source feed: China

> China NMPA drug inspection for Guangzhou Xiangxue Pharmaceutical Co., Ltd. published February 13, 2020. Drug: Antiviral oral liquid. On February 13, 2020, the Guangdong Provincial Drug Administration issued Announcement No. 10, detailing the results of 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from the Guangdong Provincial Drug Administration Regarding Information on Drug Supervision and Sampling Inspections for COVID-19 Prevention and Control (First Batch)
- Company Name: Guangzhou Xiangxue Pharmaceutical Co., Ltd.
- Publication Date: 2020-02-13
- Drug Name: Antiviral oral liquid
- Inspection Finding: Compliant
- Summary: On February 13, 2020, the Guangdong Provincial Drug Administration issued Announcement No. 10, detailing the results of the first batch of drug quality inspections conducted during the COVID-19 prevention and control period. This regulatory action was performed under the framework of the National Medical Products Administration (NMPA) and provincial government mandates to strengthen post-market supervision of essential medications. The inspections focused on pharmaceutical manufacturers and distributors to ensure the safety of drugs used in epidemic response. Two specific companies were highlighted in this report: Guangzhou Xiangxue Pharmaceutical Co., Ltd. and Guangzhou Nanxin Pharmaceutical Co., Ltd. Quality control specialists sampled five batches of critical products, specifically antiviral oral liquids and peramivir sodium chloride injections. Testing conducted by the Guangdong Provincial Institute for Drug Control confirmed that all samples met the necessary quality standards. Because no violations or safety issues were identified in this batch of inspections, no corrective or disciplinary actions were required. The announcement serves as a professional confirmation of regulatory compliance for these specific COVID-19-related medical products during the initial phase of the public health emergency.

Company: https://www.globalkeysolutions.net/companies/guangzhou-xiangxue-pharmaceutical-co-ltd/2f0bbb93-dce8-47c2-84f9-4c7ade5a4f2e/